Lung cancer is the malignant transformation and expansion of lung tissue, and is the most lethal of all cancers worldwide, responsible for 1.2 million deaths annually. It is caused predominantly by cigarette smoking, and predominantly affected men, but with increased smoking among women, it is now the leading cause of death due to cancer in women. However, some people who have never smoked still get lung cancer. Current research indicates that the factor with the greatest impact on risk of lung cancer is long-term exposure to inhaled carcinogens. The most common means of such exposure is air pollution and tobacco smoke.
Treatment and prognosis depend upon the histological type of cancer, the stage (degree of spread), and the patient's performance status. Treatments include surgery, chemotherapy, and radiotherapy.
703D4
recognizes
heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP-A2/B1) can
frequently detect lung cancer in exfoliated sputum epithelial
cells 1-2 years earlier than routine chest X-ray or sputum
cytomorphology.
PMID: 11714531
ADAM8
a novel
serological and histochemical marker for lung cancer.
PMID: 15623614
AGNA (Anti-glial
nuclear antibody)
marker
of lung cancer-related paraneoplastic neurological syndromes.
PMID: 15949849
ASC/TMS1
hypermethylation of ASC/TMS1 is a marker for
late-stage lung cancer and, in sputum, could predict prognosis
in patients resected for early-stage disease.
PMID: 16778195
beta-Catenin
a useful diagnostic marker for well-differentiated fetal adenocarcinoma of the lung. PMID: 17173289
CA 125
can be used as an adjunctive test in the
management of patients with lung cancer patients.
PMID: 1845935
Calcitonin
serial measurement of plasma calcitonin is
useful in the management of the patient with small cell
carcinoma of the lung.
PMID: 6267098
Cathepsin K
selectively expressed in the stroma of lung adenocarcinoma but
not in bronchioloalveolar carcinoma. A useful marker of invasive
growth.
PMID: 16690483
CD24
an independent prognostic marker of survival in nonsmall cell lung cancer patients. PMID: 12610508
cdc25B
a
prognosis marker in non-small cell lung cancer.
PMID: 11597794
CEA (carcinoembryonic antigen)
serum CEA level can be a predictive factor
for the efficacy of gefitinib treatment while it is also a
prognostic factor for advanced non-small cell lung cancer
(NSCLC) patients undergoing this treatment.
PMID: 15939264
COX-2
(Cyclooxygenase-2)
a
marker of poor prognosis in stage I non-small cell lung cancer.
PMID: 11309334
CYFRA
may be a marker of choice for screening and
monitoring of lung cancer, particularly squamous cell carcinoma.
PMID: 8933183
CYFRA21-1
a soluble fragment of cytokeratin 19 in serum
of patients with NSCLC. It can be used as a useful tumor marker
of non-small cell lung carcinoma (NSCLC).
PMID: 11776818
a tumor marker that helps to establish the
diagnosis and differentiation of cell type and evaluation of
response to therapy in patients with non-small cell lung
carcinoma (NSCLC).
PMID: 11479694
a sensitive and specific tumor marker of
non-small cell lung cancer, especially of squamous cell
carcinoma.
PMID: 11263296
may be a useful tumor marker in NSCLC,
especially in carcinoma planocellulare. CYFRA 21-1 may also be
useful in identification of the preoperative stages of diseases
and the postoperative monitoring of NSCLC.
PMID: 9887620
For patients with NSCLC, especially in
squamous cell carcinoma, CYFRA 21-1 is not only a sensitive and
specific tumor marker, but also may be a useful adjunctive
marker for disease monitoring.
PMID: 8635383
may be a useful tumor marker in NSCLC,
especially in squamous cell carcinoma. However, CYFRA 21-1
cannot be used for the diagnosis of early stage disease of
NSCLC. CYFRA 21-1 may also contribute to the monitoring of
NSCLC.
PMID: 8709175
has high sensitivity, specificity and
positive predictive value in the diagnostics of SQCLC.
Sensitivity of CYFRA 21-1 is significantly higher than
sensitivity of CEA in this setting.
PMID: 8841502
The data confirm the high sensitivity and
specific of Cyfra 21-1 for the differential diagnosis between
malignant and non-malignant pulmonary diseases as well as small
cell and non-small cell lung cancer.
PMID: 7533887
is of value in diagnosis of lung cancer,
particularly squamous cell carcinoma.
PMID: 9658744
FAS
a reliable marker of low-stage clinically aggressive lung carcinomas. PMID: 15736468
FHIT
methylation of FHIT is
a useful biomarker of biologically aggressive disease in
patients with NSCLC.
PMID: 15042681
Gamma-Enolase
Serum gamma-enolase
value is a useful tumor marker for staging and monitoring
treatment of patients with lung cancer, and serum gamma/alpha +
gamma value may be useful for differential diagnosis of SCCL
from non-SCCL or in differentiating lung cancers possessing
neuroendocrine features from other lung cancers.
PMID: 3036329
GRP (gastrin-releasing peptide)
plasma GRP level could be a useful tumor
marker in small cell lung carcinoma (SCLC) patients.
PMID: 2169019
known to be a very common product of small
cell lung carcinoma (SCLC).
PMID: 2535962
GST-mu
Smokers with the GST-mu enzyme have
approximately one-third of the risk for lung carcinoma of
smokers without the enzyme.
PMID: 8485718
HDGF (Hepatoma-derived growth factor)
a useful prognostic marker for patients with
completely resected NSCLC and it may play a critical role in the
pathobiology of lung cancer through its mitogenic and angiogenic
activities.
PMID: 15870924
Histidine Decarboxylase
useful to distinguish
between small cell lung carcinoma and non-neuroendocrine
carcinoma and to demonstrate neuroendocrine differentiation.
PMID: 12527716
HPV DNA
the presence of HPV DNA in the blood
circulation may serve as a feasible risk marker of lung cancer.
PMID: 12627521
hTERT
superior to other tumor markers in lung
cancer diagnosis.
PMID: 17052260
gene amplification is an important mechanism
for hTERT overexpression in lung adenocarcinoma and is an
independent poor prognostic marker for disease-free survival in
NSCLC.
PMID: 16641908
IA-1
a candidate marker of neuroendocrine
differentiation of human lung tumors.
PMID: 8364910
ICTP and TIMP-1
are good prognostic markers in lung cancer.
PMID: 11410500
Keratin 7
useful in
differentiating between squamous cell carcinoma and
adenocarcinoma of the lung and it may be particularly useful in
making the correct diagnosis in small lung biopsy specimens.
PMID: 7679658
Ki67
seems promising in identifying low and high
grade disease in the initial stage of lung cancer.
PMID: 9783030
KM195
the immunohistochemistry for KM195 may be a
more useful marker over CAM 5.2 for the diagnosis of pulmonary
adenocarcinoma.
PMID: 8865122
KP16D3
may be useful as a prognostic marker for
patients with stage I primary lung adenocarcinoma. Conversely,
use of this marker and subtyping of lung adenocarcinomas reflect
the prognosis of the disease.
PMID: 8377507
K-ras
The presence of K-ras point mutations defines
a subgroup of patients with lung adenocarcinoma in whom the
prognosis is very poor and disease-free survival is not usually
long despite radical resection and a small tumor load.
PMID: 2199829
LCAP (Lung Cancer Associated Protein)
as detected by MAb TRD-L1 is a potentially
useful marker for the evaluation of patients with lung cancer.
PMID: 9342632
a new and potentially useful marker for the
evaluation of patients with lung cancer.
PMID: 1855201
LDH (lactate dehydrogenase)
the combined determination of serum LDH and
NSE levels gives valuable data on the primary tumor mass and its
proliferative activity in small cell lung cancer.
PMID: 2849799
LSA (lipid-bound sialic acid)
serum LSA may be a useful biochemical marker
in lung cancer patients.
PMID: 2077205
LUNX
a potential diagnostic method for detection
of micrometastases in lymph nodes of non-small-cell lung-cancer
(NSCLC) patients.
PMID: 11251963
MAP-2 (Microtubule-associated protein 2)
recommend to be added
to immunohistochemical panels to separate non-neuroendocrine
from neuroendocrine lung tumors.
PMID: 11557784
Napsin
a promising marker for the diagnosis of primary lung adenocarcinoma. PMID: 12698189
NCAM (neural cell adhesion molecules)
NCAM is, along with NSE, a potential tumor
marker for with small cell lung cancer (SCLC).
PMID: 8391379
a
surface marker for human small cell lung cancer cells.
PMID: 2165922
Neopterin
a
novel marker for cell-mediated immunity in patients with
pulmonary tuberculosis and lung cancer.
PMID: 11243956
NRSF (neuron-restrictive silencer factor)
NRSF splice variant represents a specific
clinical marker that could prove useful in detection of the
majority of SCLCs.
PMID: 10766169
NSE (Neuron-specific enolase)
the most frequently elevated tumor marker for
patients with small cell lung cancer (SCLC) at diagnosis.
PMID: 8391379
could be of aid in the
early diagnosis of solitary pulmonary nodules and lung cancer.
PMID: 8062188
a
useful tumor marker for small cell lung cancer.
PMID: 2155054
demonstrated
immunohistologically both in small cell and non-small cell
bronchial carcinoma tissue, but high NSE levels were
predominantly present in small cell carcinomas.
PMID: 2846253
a marker for lung
carcinoma which exhibit the properties of neuroendocrine tumors
and is not a marker for histogenesis of small cell carcinoma of
the lung.
PMID: 6086970
may be a useful marker for monitoring the
clinical course of lung carcinoma, especially of SCCL.
PMID: 6305752
a well known marker of small cell lung
cancer, is also a useful marker in non-small cell lung cancer
(NSCLC) and a significant predictor of survival, independently
of the other prognostic factors.
PMID: 12928122
one of the most widely used tumor markers in
small-cell lung carcinoma (SCLC).
PMID: 7964990
Serum NSE determination seems to be a
valuable tool for the diagnosis of small cell carcinoma.
PMID: 2983452
There was a good correlation between serum
NSE levels and the clinical course of patients with small-cell
carcinoma of lung (SCCL).
PMID: 6095430
a
useful diagnostic marker for small cell lung cancer pleurisy.
PMID: 2537710
Osteopontin (OPN)
large increase in OPN
expression in tumors compared with normal tissue and its
association with survival suggest a role for OPN in lung
tumorigenesis.
PMID: 15014008
p16M
a
possible marker of advanced stage in non-small cell lung cancer.
PMID: 11815997
p31
expression occurs in both non-neoplastic and
neoplastic epithelium of the human respiratory tract. The
increased expression of p31 in the peripheral lung may be
potentially informative as to what critical cell populations are
involved in the development of invasive cancers.
PMID: 8696723
p53
Analysis of p53 gene mutations was thus
useful in distinguishing second primary lung cancers from
recurrent tumors.
PMID: 9305187
p63 and TTF-1
appear to be useful for differentiating small
cell lung carcinoma (SCLC) from lung poorly differentiated
squamous cell carcinoma (PDSCC) in formalin-fixed and
alcohol-fixed, formalin-postfixed material.
PMID: 12760288
PAI-2 (plasminogen activator inhibitor 2)
may be useful as a marker for evaluating the
prognosis of lung cancer.
PMID: 9743310
PGP9.5
specifically associated with lung cancer
development and may serve as a potential marker for the
detection of lung cancer.
PMID: 10487828
PKP3 (plakophilin 3)
might hold promise for development of a new
therapeutic and diagnostic strategy for clinical management of
lung cancers.
PMID: 16103059
Progastrin-releasing peptide (proGRP)
a precursor of gastrin-releasing peptide, a
hormone which is secreted from neuroendocrine cells. It has been
shown to be a useful serum marker for small cell lung cancer.
PMID: 17287611
Pro-GRP (Gastrin-releasing peptide )
a member of the bombesin family of peptides,
may be a potential tumor marker for small cell lung carcinoma.
PMID: 12820319
the determination of serum ProGRP(31-98) was
a reliable marker for small-cell lung carcinoma (SCLC).
PMID: 7720242
serum Pro-GRP has high specificity and could
be a useful marker of SCLC for treatment monitoring and
prognosis.
PMID: 10461062
ProGRP(31-98)
the determination of serum ProGRP(31-98)
levels plays an important role in the diagnosis and treatment of
small cell lung carcinoma (SCLC) patients.
PMID: 8174119
the determination of
serum ProGRP(31-98) levels plays an important role in the
diagnosis and treatment of SCLC patients.
PMID: 8630283
Rad51
an
independent prognostic marker of survival in non-small-cell lung
cancer patients.
PMID: 15956972
RAS
ras gene mutations may be prognostic,
especially in the early stage adenocarcinoma of the lung.
PMID: 1581907
RCAS1
determination at onset of pleural effusion is
informative for both diagnosis and outcome prediction in lung
cancer patients.
PMID: 16773186
S100A2
expression of the S100A2 protein in stage I
NSCLC indicates poor prognosis and may be used to identify
patients with early-stage NSCLC who might benefit from adjuvant
treatment.
PMID: 15800916
SAG (sensitive to apoptosis gene)
SAG gene expression in
non small cell lung cancer (NSCLC) may be a useful prognostic
marker.
PMID: 11668520
SEZ6L2
a useful prognostic
marker of lung cancers.
PMID: 16863507
Smac
play a role in the carcinogenesis,
progression, and prognosis of primary lung cancer.
PMID: 15010875
spr1
a sensitive and specific marker for squamous bronchogenic carcinoma. PMID: 9699184
Survivin
the expression of
survivin in tumor cells is a factor of poor prognosis in
patients with small adenocarcinoma of the lung.
PMID: 12066218
TACC3
(transforming acidic coiled-coil containing protein 3)
a
novel independent prognostic marker in non-small cell lung
cancer.
PMID: 16930330
T antigen (Thomsen-Frienden-reich antigen)
The presence of T antigen immunoreactivity in
tumor cells is a useful marker of prognosis in patients with
pulmonary adenocarcinoma.
PMID: 10023001
Telomerase
detection of telomerase protein in
noncancerous bronchial epithelia will become a useful marker
detecting high-risk patients for lung cancer development.
PMID: 16266979
Tenascin (Tn)-C
may play an important role in angiogenesis of
patients with NSCLC, and the determination of serum Tn-C may be
useful in predicting intratumoral vasculature and patients'
prognosis.
PMID: 15816617
TGF beta 1
Elevated plasma TGF beta 1 levels occur
frequently in patients with lung cancer. In those patients with
an elevated plasma TGF beta 1 level at diagnosis, monitoring
this level may be useful in detecting both disease persistence
and recurrence after therapy.
PMID: 9017584
Thy-1
maybe a novel latent malignant marker in the
lung cancer pathology.
PMID: 16255990
TLP (Tumour Liberated Proteins)
a 214 kDa protein,
isolated from lung cancer tissue,
is a
new tumour associated antigen of non-small cell lung cancer
and could represent an useful tumour marker.
PMID: 8694552
TTF-1 (thyroid transcription factor-1)
In tissue sections,
TTF-1 is a sensitive marker for adenocarcinomas of lung and
thyroid origin. In cytologic preparations, TTF-1 is a highly
selective marker for pulmonary adenocarcinoma and also can have
a role in the distinction between pulmonary adenocarcinoma and
mesothelioma.
PMID: 11601132
Tumor M2-PK
With the fuzzy logic method and a tumor
marker panel (including the new marker Tumor M2-PK), a useful
diagnostic tool for the detection of progression in lung cancer
patients is available.
PMID: 12820320
VEGF
The combination of VEGF and CEA was superior
to CEA alone in the early diagnosis of adenocarcinoma of the
lung.
PMID: 12521132
YB-1 (Y-box
binding protein 1)
a
negative prognostic marker in nonsmall cell lung cancer.
PMID: 14738225
a
novel marker of disease progression in non-small cell lung
cancer.
PMID: 11595709
Other Lung Cancer Markers
The combination of NSE and pro-GRP is more
appropriate than other combinations in diagnosing small-cell
lung cancer; the combination of CYFRA21-1, CEA and p53 antibody
is the most valuable combination for diagnosing non-small-cell
lung cancer. p53 antibody has the highest specificity for
diagnosing lung cancer; CYFRA21-1 is the most valuable parameter
for diagnosing squamous carcinoma.
PMID: 15996327
Plasma DNA microsatellite panel as sensitive and tumor-specific
marker in lung cancer patients.
PMID: 12704670
Fuzzy logic-based tumor-marker profiles improved sensitivity in
the diagnosis of lung cancer.
PMID: 12109515
18F-FDG coincidence imaging is a powerful tool for evaluating patients with
lung lesions suggestive of malignancy. Although the
determination of serum marker levels is less accurate than
18F-FDG coincidence imaging, the combination of a positive
18F-FDG coincidence result and positive tumor markers may be
helpful in improving the diagnosis of lung cancers.
PMID: 17274375
measuring multiple tumor markers was of
clinical value in monitoring the clinical course of cancer
patients as well as in assisting the diagnosis of lung cancer.
PMID: 2018388
plasma DNA may be a useful marker in patients
with lung cancer.
PMID: 2243459
quantitative cytosine methylation profiling
can be used to identify molecular classification markers in lung
cancer.
PMID: 17108128
Increased collagenase activity in macrophages from bronchial
lavage as a diagnostic marker of non-small cell lung cancer.
PMID: 12554893
tetanus toxin labeling may become a useful
diagnostic marker for SCLC cells in cytology.
PMID: 2558117
Determinations of CABLA could thus be a
potential and valuable marker for a subset of SCLC.
PMID: 2556168
serum pseudouridine may be a useful
biochemical marker in the patients with SCLC.
PMID: 2822241
free EBV DNA can be detected in the serum of
patients with LELC of the lung and further suggests the
feasibility of its use for monitoring response to therapy in
advanced cases.
PMID: 11948104
the
use of diacylglycerol measurement as a novel biomarker for early
detection of lung cancer, and for monitoring recurrences after
treatment.
PMID: 8882982
For distinguishing between epithelioid
mesothelioma and lung adenocarcinoma, the combination of CEA,
calretinin and each WT1 or thrombomodulin was suggested to be
the best panel of immunohistochemical markers.
PMID: 17316414